stonks4u
Sign up free
INKT logo

INKT MiNK Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$11.27
+0.27 (+2.45%)

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune…

Market Cap: $56.15Mminktherapeutics.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

107
107
Aug 13Aug 13

Quote

Day Range
$10.95 – $11.73
52-Week Range
$8.48 – $16.98
Volume
$6.8K
Market Cap
$56.15M
50-Day Avg
$11.34
200-Day Avg
$11.51
Prev Close
$11.00
Open
$11.10

Valuation & Ratios

P/E Ratio
-3.81
EPS
$-2.93
P/B Ratio
-3.35
P/S Ratio
0.00
Debt/Equity
-0.36
Current Ratio
1.06
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
+87.8%
Return on Assets
-87.7%
FCF Yield
-12.4%
EV/EBITDA
-3.20

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-12.49M$-2.93
2024$0.00$-10.78M$-2.90
2023$0.00$-22.46M$-6.54
2022$0.00$-27.99M$-8.31
2021$0.00$-30.21M$-9.03

Social Signal Score

58
5d
58
3 mentions
—
30d
58
3 mentions
—
60d
58
3 mentions
—
90d
58
3 mentions
—
news: 3

Earnings

Thu, Nov 12(in 3 months)

Consensus estimate $-0.63 per share

3of 7 quarters beat consensus

Typical surprise -3.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.62 vs $-0.60miss
  • Fri, May 15$-0.57 vs $-0.77beat
  • Tue, Mar 17$-0.52 vs $-0.68beat
  • Fri, Nov 14$-0.65 vs $-0.86beat
  • Thu, Aug 14$-1.06 vs $-0.55miss
  • Thu, May 15$-0.70 vs $-0.61miss

Estimates and results for INKT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

INKThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsseekingalpha.com·2d ago·Positive

    MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·2d ago·Neutral

    MiNK Therapeutics Q2 Earnings Call Highlights MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.

    View source ↗
  • Newsglobenewswire.com·2d ago·Neutral

    …and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders, today reported financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797.

    View source ↗